Meiji Seika Pharmatech CO Limited Pharmaceutical Import Profile — Japan (DGFT 2022–2026)

Name: Meiji Seika Pharmatech CO Limited Pharmaceutical Import Records from India — 4 Products, $5.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Meiji Seika Pharmatech CO Limited — Pharmaceutical Importer Profile (2026) | 4 Products, $5.1M Trade | TransData Nexus

Meiji Seika Pharmatech CO Limited

Pharmaceutical Importer · Japan · Cardiovascular Focus · $5.1M Total Trade · DGFT Verified

Meiji Seika Pharmatech CO Limited is a pharmaceutical importer based in Japan with a total trade value of $5.1M across 4 products in 3 therapeutic categories. Based on 102 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Meiji Seika Pharmatech CO Limited sources from 1 verified Indian supplier, with Medreich Limited accounting for 100.0% of imports.

Meiji Seika Pharmatech CO Limited — Import Portfolio & Supplier Network

Meiji Seika Pharmatech CO Limited import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Meiji Seika Pharmatech CO Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Medreich Limited	$2.9M	72	100.0%

Meiji Seika Pharmatech CO Limited sources from 1 verified Indian supplier across 40 distinct formulations. The sourcing is highly concentrated — Medreich Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Meiji Seika Pharmatech CO Limited Import?

Formulation	Value	Ships
Atorvastatin tablets 10MG	$439.9K	9
Rebamipide 100MG tablets rebamipide	$300.0K	6
Pravastatin sodium 10MG tablets po	$300.0K	6
Glimepiride 1MG tablets po	$293.3K	8
Glimepiride 0.5MG tablets po	$249.8K	5
Pravastatin sodium 5MG tablets, po	$100.0K	2
Rosuvastatin od tablets 2.5MG po	$61.3K	2
Pravastatin 10mgtabs 40000s-nn-nissin/ja	$50.0K	1
Famotidine 20MG tablets, po no.mm-161	$50.0K	1
Pravastatin 5mgtabs 70000s-nn-nissin/jap	$50.0K	1
Rebamipide100mg TAB 30000s-nn-nissin/japan po no.mm-152 Pack size:30000	$50.0K	1
Mosapride citrate tablets jp 5MG po no.mm-160 dtd 22.02.2023 Pack	$50.0K	1
Pravastatin sodium 5MG tablets po no.mm-153 Pack size:70000s	$50.0K	1
Atorvastatin tablets 10MG atorvastatintablets 10MG meiji po no.mm-157 packsize:56818 no	$50.0K	1
Famotidine 20MG tablets po no.mm-163 dtd 29.05.2023 Pack size:55556 no	$50.0K	1

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Pravastatin	Cardiovascular	$2.0M	40	3.5%	4
2	Glimepiride	Diabetes & Endocrine	$1.4M	28	0.9%	3
3	Amlodipine	Cardiovascular	$1.1M	22	0.0%	18
4	Famotidine	Gastrointestinal	$600.0K	12	1.1%	12

Meiji Seika Pharmatech CO Limited imports 4 pharmaceutical products across 3 categories into Japan totaling $5.1M.

Meiji Seika Pharmatech CO Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Meiji Seika Pharmatech Co., Ltd. is a Japanese pharmaceutical company specializing in the manufacturing of prescription pharmaceuticals and related services. Established on December 1, 2022, as a wholly-owned subsidiary of Meiji Seika Pharma Co., Ltd., the company succeeded the functions of the Odawara Plant, which had been providing a stable supply of high-quality pharmaceutical formulations for over 30 years. (meiji-seika-pharma.co.jp) The company is headquartered at 1056 Kamonomiya, Odawara-shi, Kanagawa-ken, Japan.

Meiji Seika Pharmatech Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO), offering comprehensive services from formulation and manufacturing process development to commercial production. The company produces a variety of pharmaceutical formulations, including antibacterial agents, generic drugs, and vaccines, catering to both domestic and international markets. By leveraging over 70 years of experience and technological expertise, Meiji Seika Pharmatech aims to meet the diverse needs of clients and support them in overcoming challenges across new modalities. (meiji-seika-pharma.co.jp)

2Distribution Network

Meiji Seika Pharmatech Co., Ltd. operates a centralized distribution network from its manufacturing facility in Odawara, Kanagawa Prefecture. The company focuses on ensuring a stable and reliable supply of pharmaceutical products to various stakeholders, including wholesalers, hospitals, and pharmacies across Japan. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic location in Odawara provides efficient access to major transportation routes, facilitating timely distribution within Japan. Meiji Seika Pharmatech's commitment to quality assurance and compliance with Good Manufacturing Practice (GMP) standards underscores its dedication to maintaining the integrity of its distribution network. (meiji-seika-pharma.co.jp)

3Industry Role

In Japan's pharmaceutical supply chain, Meiji Seika Pharmatech Co., Ltd. functions primarily as a Contract Development and Manufacturing Organization (CDMO). The company specializes in the manufacturing of prescription pharmaceuticals, including antibacterial agents, generic drugs, and vaccines, serving both domestic and international markets. By offering comprehensive services from formulation and manufacturing process development to commercial production, Meiji Seika Pharmatech plays a pivotal role in ensuring a stable and reliable supply of high-quality pharmaceutical products.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Meiji Seika Pharmatech CO Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Meiji Seika Pharmatech Co., Ltd. demonstrates a high degree of sourcing concentration, importing finished pharmaceutical formulations exclusively from a single supplier, Medreich Limited, based in India. Between 2022 and 2026, the company imported products totaling $5.1 million USD across 102 shipments, with Medreich Limited accounting for 100% of these imports. This sourcing strategy indicates a strong, long-term partnership between Meiji Seika Pharmatech and Medreich Limited. The consistent volume of imports over the years suggests a stable and reliable supply chain relationship. However, this single-source dependency may pose risks related to supply chain disruptions, currency fluctuations, and geopolitical factors affecting trade between Japan and India. Diversifying the supplier base could mitigate these risks and enhance supply chain resilience.

2Supply Chain Resilience

Meiji Seika Pharmatech Co., Ltd.'s supply chain resilience is closely tied to its exclusive partnership with Medreich Limited in India. The company's import data indicates a consistent and reliable supply of finished pharmaceutical formulations, with Medreich Limited accounting for all imports between 2022 and 2026. While this strong partnership ensures product quality and consistency, the lack of alternative suppliers may expose Meiji Seika Pharmatech to risks such as supply chain disruptions, regulatory changes, or geopolitical tensions affecting trade between Japan and India. To enhance resilience, the company could consider establishing relationships with additional suppliers and diversifying its sourcing strategy.

Importing Pharmaceuticals into Japan — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Japan

1Regulatory Authority & Framework

In Japan, the Ministry of Health, Labour and Welfare (MHLW) serves as the primary regulatory authority overseeing pharmaceutical imports. The Pharmaceutical Affairs Law governs the importation, manufacturing, and distribution of pharmaceutical products in Japan. To market pharmaceutical products in Japan, foreign manufacturers must obtain marketing authorization from the MHLW, which involves submitting a New Drug Application (NDA) that includes comprehensive data on the product's safety, efficacy, and quality. The MHLW evaluates the application to ensure that the product meets Japanese standards before granting approval. This regulatory framework ensures that imported pharmaceutical products, including those from India, are safe and effective for the Japanese market.

2Import Licensing & GMP

Import licensing requirements in Japan stipulate that foreign pharmaceutical manufacturers must obtain marketing authorization from the Ministry of Health, Labour and Welfare (MHLW) to sell their products in the country. This process involves submitting a New Drug Application (NDA) that includes detailed information on the product's safety, efficacy, and quality. Good Manufacturing Practice (GMP) certification is a critical component of this process. The MHLW recognizes GMP certifications from various international standards, including EU GMP, WHO GMP, and PIC/S. Foreign manufacturers must provide evidence of compliance with these standards to demonstrate their commitment to producing high-quality pharmaceutical products. Additionally, wholesale distribution authorization is required for companies involved in the distribution of pharmaceutical products within Japan. This authorization ensures that distributors adhere to Japanese regulations and maintain the integrity of the pharmaceutical supply chain.

Meiji Seika Pharmatech CO Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Meiji Seika Pharmatech Co., Ltd. focuses its product strategy on therapeutic areas with significant market demand, including cardiovascular diseases, diabetes and endocrine disorders, and gastrointestinal conditions. The company's import data indicates a concentration in these categories, with cardiovascular products accounting for 60.8% of imports, diabetes and endocrine products 27.5%, and gastrointestinal products 11.8%. This strategic focus aligns with the aging population in Japan and the increasing prevalence of chronic diseases, driving the demand for effective treatments in these therapeutic areas.

2Sourcing Profile

Meiji Seika Pharmatech Co., Ltd. employs a sourcing strategy that relies exclusively on a single supplier, Medreich Limited in India, for its finished pharmaceutical formulations. This approach ensures consistency and quality in the products imported into Japan. The company's import data reveals a diverse range of 40 unique formulations, indicating a broad portfolio within its therapeutic focus areas. India's established pharmaceutical manufacturing capabilities and cost-effectiveness make it a strategic partner for Meiji Seika Pharmatech's sourcing needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to Meiji Seika Pharmatech CO Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Meiji Seika Pharmatech Co., Ltd., especially if they can offer competitive pricing, ensure compliance with Japanese regulatory standards, and demonstrate the ability to meet the company's quality and supply requirements.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Meiji Seika Pharmatech CO Limited

What products does Meiji Seika Pharmatech CO Limited import from India?

Meiji Seika Pharmatech CO Limited imports 4 pharmaceutical products across 3 categories. Top imports: Pravastatin ($2.0M), Glimepiride ($1.4M), Amlodipine ($1.1M), Famotidine ($600.0K).

Who supplies pharmaceuticals to Meiji Seika Pharmatech CO Limited from India?

Meiji Seika Pharmatech CO Limited sources from 1 verified Indian suppliers. The primary supplier is Medreich Limited (100.0% of imports, $2.9M).

What is Meiji Seika Pharmatech CO Limited's total pharmaceutical import value?

Meiji Seika Pharmatech CO Limited's total pharmaceutical import value from India is $5.1M, based on 102 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Meiji Seika Pharmatech CO Limited focus on?

Meiji Seika Pharmatech CO Limited imports across 3 categories. The largest: Cardiovascular (60.8%), Diabetes & Endocrine (27.5%), Gastrointestinal (11.8%).

Get Full Meiji Seika Pharmatech CO Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.